DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2194205/wall-street-analysts-see-a-56-25-upside-in-alpine-immune-sciences-inc-alpn-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2194205 Dec 06, 2023 - The mean of analysts' price targets for Alpine Immune Sciences, Inc. (ALPN) points to a 56.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. 0

https://www.zacks.com/stock/news/2194207/wall-street-analysts-see-a-25-69-upside-in-legacy-housing-legh-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2194207 Dec 06, 2023 - The average of price targets set by Wall Street analysts indicates a potential upside of 25.7% in Legacy Housing (LEGH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. 0

https://www.rttnews.com/story.aspx?Id=3409906 Dec 06, 2023 - Following the lackluster performance seen in the previous session, stocks may move to the upside in early trading on Wednesday. Early buying interest may be generated in reaction to a report from payroll processor ADP showing private sector employment in the U.S. increased by less than expected in the month of November. 0

https://www.zacks.com/stock/news/2193852/jolts-data-tame-most-indices-see-profits-booked?cid=CS-ZC-FT-ahead_of_wall_street-2193852 Dec 05, 2023 - JOLTS results came in lower than expected: 8.7 million domestic job openings fell -617K from the previous month's downwardly revised 9.4 million. 0

https://www.zacks.com/stock/news/2193841/agnc-investment-agnc-sees-a-more-significant-dip-than-broader-market-some-facts-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2193841 Dec 05, 2023 - In the most recent trading session, AGNC Investment (AGNC) closed at $9, indicating a -0.88% shift from the previous trading day. 0

https://www.cnbc.com/2023/12/05/bernstein-names-amazon-its-best-idea-and-we-see-a-lot-to-like-too-.html Dec 05, 2023 - Club holding Amazon (AMZN) is a stock to own going into 2024, with the ecommerce giant poised for further profitability, according to Bernstein Research. 0

https://www.zacks.com/stock/news/2193633/wall-street-analysts-see-a-42-55-upside-in-krystal-biotech-inc-krys-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2193633 Dec 05, 2023 - The mean of analysts' price targets for Krystal Biotech, Inc. (KRYS) points to a 42.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. 0

https://seekingalpha.com/news/4043124-barclays-cuts-immunogen-to-equal-weight-doesnt-see-more-bidders?source=feed_sector_healthcare Dec 04, 2023 - Barclays downgraded ImmuoGen (IMGN) to equal weight, stating that it doesn't see any other bidders emerging in the wake of AbbVie’s $10B offer for the company. Read more here. 0

https://seekingalpha.com/news/4043108-rbc-sees-sareptas-elevidys-remaining-on-market-report?source=feed_sector_healthcare Dec 04, 2023 - RBC said it was highly likely that the FDA will allow Sarepta's (SRPT) drug Elevidys for Duchenne muscular dystrophy to remain on the market. Read more here. 0

https://seekingalpha.com/news/4042633-piper-sees-glp-1-drugs-increasing-demand-for-knee-hip-surgeries-near-term?source=feed_sector_healthcare Dec 03, 2023 - Piper Sandler said it expects upcoming results from a Novo Nordisk (NVO) study of its weight-loss drug semaglutide in the treatment of osteoarthritis to be “med 0